ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO367

Association Between N-Terminal pro-B-Type Natriuretic Peptide with CKD Progression in the CKD in Children Cohort

Session Information

  • Pediatric Nephrology - III
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology


  • Kula, Alexander J., Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
  • Prince, David K., University of Washington, Seattle, Washington, United States
  • Flynn, Joseph T., Seattle Children's Hospital, Seattle, Washington, United States
  • Bansal, Nisha, University of Washington, Seattle, Washington, United States

Elevations in the serum biomarker N-terminal pro B-type natriuretic peptide (NT-proBNP) are strongly associated with CKD progression in adults. It is unknown whether these associations are also seen in children with CKD, and may help identify a novel risk factor in this population. The objective of this study was to examine the association of NT-proBNP with CKD progression in youth with mild to moderate CKD.


We measured serum NT-proBNP at the baseline visit of participants with available samples enrolled in the Chronic Kidney Disease in Children (CKiD) study (N=493). Included participants were aged 1-18 years with an eGFR of 30-90mL/min/1.73m2. Exclusion criteria included history of kidney transplant, dialysis < 3 months, or structural heart disease. CKD progression was defined as a 40% decline in eGFR and/or progression to ESKD. We utilized nested Cox proportional hazards models to test the association between baseline NT-proBNP with CKD progression.


Mean ±SD baseline NT-proBNP and eGFR were 127 ±173pg/mL and. 55 ±21mL/min/1.73m2, respectively. Median duration of follow-up was 3.9 years and 107 (22%) met criteria for CKD progression. In unadjusted models, NT-proBNP was associated with CKD progression (HR, [95% CI] per doubling: 1.36, [1.18, 1.56]). NT-proBNP was not associated with CKD progression in adjusted models (HR, [95% CI] per doubling: 1.06 [0.87, 1.29]). There was no interaction for participants with an eGFR above or below 45mL/min/1.73m2 (p= 0.84). Absolute and relative decline in eGFR was not different across baseline quartiles (Figure 1).


Unlike adults with CKD, NT-proBNP was not associated with CKD progression in a large, well-characterized cohort of youth with CKD. Potential explanations include physiologic differences across the lifespan and/or relatively short duration of follow-up.


  • Private Foundation Support